That is to say, more poised epigenetic states in individual tumors belonging to certain subtypes of HER2+ tumor cells might generate higher degrees of diversity in gene expression patterns that can rapidly evolve through trastuzumab selection during treatment, thus driving multistep epigenetic fixation of gene expression in response to trastuzumab-based therapy. This evidence concerns the gene ERBB2 and neoplasm.